If you liked this article you might like

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market
Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO
Biotech Premarket Movers: Insys, Ultragenyx, Alexion